Novltreat 1

Noveltreat 1mg Injection contains Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is supplied as a pre-filled pen containing Semaglutide 1 mg/0.5 mL and is intended for subcutaneous use once weekly. It is marketed by Sun Pharmaceutical Industries Ltd. Noveltreat 1mg Injection is indicated for chronic weight management in adults with obesity or overweight with certain weight-related health conditions. It is used along with a reduced-calorie diet and increased physical activity as part of a long-term weight management plan.

Noveltreat 1mg Injection may be prescribed for: Chronic weight management: It is used along with a reduced-calorie diet and increased physical activity to support weight loss and long-term weight management in adults with obesity. Overweight with weight-related health conditions: It may be prescribed for adults who are overweight and have certain weight-related health conditions, as determined by the doctor. The dose is increased gradually according to the treatment plan prescribed by the doctor. Do not change the dose without medical advice.

Noveltreat 1mg Injection is given as a subcutaneous injection once weekly, exactly as prescribed by your doctor. It can be injected into the abdomen, thigh, or upper arm and may be used at any time of the day, with or without food. Use it on the same day each week according to your prescribed schedule. Your doctor or healthcare professional should show you how to use the pre-filled pen before your first injection. Do not inject Noveltreat into a vein or muscle.

Common side effects of Noveltreat 1mg Injection may include: Nausea Vomiting Diarrhoea Constipation Abdominal or stomach pain Reduced appetite Headache Tiredness These effects may be more noticeable when treatment is started or the dose is increased and may improve as the body adjusts to treatment. Seek medical attention if you develop severe or persistent abdominal pain, especially if it spreads to the back, as this may indicate pancreatitis. Tell your doctor if you develop symptoms that could indicate gallbladder problems or a serious allergic reaction.

Pregnancy Unsafe Noveltreat should not be used during pregnancy unless specifically advised by a doctor. If you become pregnant while using Semaglutide, contact your doctor promptly. Women planning a pregnancy should discuss treatment with their doctor beforehand. Semaglutide should generally be stopped at least 2 months before a planned pregnancy. Breast Feeding Consult Your Doctor Tell your doctor if you are breastfeeding before using Noveltreat 1mg Injection. Your doctor will decide whether treatment is appropriate based on your individual circumstances. Lungs Consult Your Doctor Semaglutide does not have specific routine lung-related precautions. Tell your doctor about any significant respiratory condition and inform your healthcare team that you are using Semaglutide before surgery or a procedure requiring anaesthesia or deep sedation. Liver Consult Your Doctor Tell your doctor if you have liver disease before starting Noveltreat 1mg Injection. Your doctor will decide whether any additional monitoring is needed. Alcohol Consult Your Doctor Discuss alcohol consumption with your doctor while using Noveltreat. Alcohol may worsen gastrointestinal symptoms such as nausea and vomiti

2 - 8°C